These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 10090319)

  • 1. Development of primary hypothyroidism with the appearance of blocking-type antibody to thyrotropin receptor in Graves' disease in late pregnancy.
    Ueta Y; Fukui H; Murakami H; Yamanouchi Y; Yamamoto R; Murao A; Santou Y; Taniguchi S; Mitani Y; Shigemasa C
    Thyroid; 1999 Feb; 9(2):179-82. PubMed ID: 10090319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
    Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
    Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The relationship between serum thyroid autoantibodies, iodine intake, development and prognosis of Graves' disease].
    Chen W; Man N; Li YS; Shan ZY; Teng WP
    Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):95-9. PubMed ID: 16624113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.
    Takasu N; Oshiro C; Akamine H; Komiya I; Nagata A; Sato Y; Yoshimura H; Ito K
    J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mechanism of spontaneous hypothyroidism in patients with Graves' disease after antithyroid drug treatment.
    Tamai H; Hirota Y; Kasagi K; Matsubayashi S; Kuma K; Iida Y; Konishi J; Okimura MC; Walter RM; Kumagai LF
    J Clin Endocrinol Metab; 1987 Apr; 64(4):718-22. PubMed ID: 2434520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A change from stimulatory to blocking antibody activity in Graves' disease during pregnancy.
    Kung AW; Jones BM
    J Clin Endocrinol Metab; 1998 Feb; 83(2):514-8. PubMed ID: 9467567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
    Choo YK; Yoo WS; Kim DW; Chung HK
    Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoglobulins of untreated Graves' patients with or without thyrotropin receptor antibody (determined by porcine thyrocytes) universally elicit potent thyroid hormone-releasing activity in cultured human thyroid follicles.
    Sato K; Yamazaki K; Yamada E; Kanaji Y; Miura M; Obara T
    Thyroid; 1999 Oct; 9(10):979-88. PubMed ID: 10560951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
    Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa.
    McLachlan SM; Rapoport B
    Thyroid; 2013 Jan; 23(1):14-24. PubMed ID: 23025526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of postpartum spontaneously resolving transient Graves' hyperthyroidism followed immediately by transient hypothyroidism.
    Shigemasa C; Mitani Y; Taniguchi S; Ueta Y; Urabe K; Tanaka T; Yoshida A; Mashiba H
    J Intern Med; 1990 Jul; 228(1):23-8. PubMed ID: 2384733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent Graves' hyperthyroidism despite rapid negative conversion of thyroid-stimulating hormone-binding inhibitory immunoglobulin assay results: a case report.
    Ohara N; Kaneko M; Kitazawa M; Uemura Y; Minagawa S; Miyakoshi M; Kaneko K; Kamoi K
    J Med Case Rep; 2017 Feb; 11(1):32. PubMed ID: 28162094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TSBAb (TSH-stimulation blocking antibody) and TSAb (thyroid stimulating antibody) in TSBAb-positive patients with hypothyroidism and Graves' patients with hyperthyroidism.
    Takasu N; Yamashiro K; Ochi Y; Sato Y; Nagata A; Komiya I; Yoshimura H
    Horm Metab Res; 2001 Apr; 33(4):232-7. PubMed ID: 11383928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of hypothyroidism with thyroid stimulation blocking antibody long after treatment with antithyroid drugs in a patient with hyperthyroid Graves' disease: a case report.
    Kasuga Y; Sugenoya A; Kobayashi S; Shimizu T; Onuma H; Shingu K; Asanuma K; Hama Y; Iida F
    Endocr J; 1993 Apr; 40(2):227-30. PubMed ID: 7524926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of thyroid stimulating antibody (TSAb) in the thyroid function of patients with post-partum hypothyroidism.
    Hara T; Tamai H; Mukuta T; Fukata S; Kuma K
    Clin Endocrinol (Oxf); 1992 Jan; 36(1):69-74. PubMed ID: 1348451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
    Maugendre D; Massart C
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two Graves' disease patients who spontaneously developed hypothyroidism after antithyroid drug treatment: characteristics of epitopes for thyrotropin receptor antibodies.
    Chung HK; Kim WB; Park DJ; Kohn LD; Tahara K; Cho BY
    Thyroid; 1999 Apr; 9(4):393-9. PubMed ID: 10319947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Graves' disease in pregnancy: prospective evaluation of a selective invasive treatment protocol.
    Nachum Z; Rakover Y; Weiner E; Shalev E
    Am J Obstet Gynecol; 2003 Jul; 189(1):159-65. PubMed ID: 12861156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of thyroid-stimulating blocking antibody in patients who developed hypothyroidism within one year after 131I treatment for Graves' disease.
    Yoshida K; Aizawa Y; Kaise N; Fukazawa H; Kiso Y; Sayama N; Hori H; Nakazato N; Tani J; Abe K
    Clin Endocrinol (Oxf); 1998 Jan; 48(1):17-22. PubMed ID: 9509063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in the properties of the thyrotropin receptor antibody in patients with Graves' disease after radioiodine treatment.
    Cho BY; Shong YK; Chung JK; Lee MC; Lee HK; Koh CS; Min HK
    Thyroidology; 1989 Dec; 1(3):109-14. PubMed ID: 2484872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.